Drug Approval | October 19, 2021
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
It has planned an investment of over Rs 80 crore in the next five years
The company plans to raise US $ 15 million
Subscribe To Our Newsletter & Stay Updated
